Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data SPRUCE BIOSCIENCES, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
10.1
4.91
0
Research and development
10.8
23.9
30.7
35.2
49.4
46.4
19.5
General and administrative
2.29
5.56
11.4
12.1
12.7
14.6
17
Operating expenses
13.1
29.4
42.1
47.3
62.1
61.1
36.5
Operating income
-13.1
-29.4
-42.1
-47.3
-52
-56.2
-36.5
Interest expense
0.07
0.32
0.35
0.42
0.48
0.31
0.09
Other non-operating income
0.08
0.2
0.12
Income tax
0
0
0
0
0
0
0
Net income
-13.1
-29.5
-42.3
-46.2
-47.9
-53
-39
EBITDA
-13.1
-29.4
-42
-47.2
-51.9
-56.1
-36.5
EPS, basic
-1,279.00
-368.41
-135.26
-146.47
-92.66
-96.40
-50.83
EPS, diluted
-1,279.00
-368.41
-135.26
-146.47
-92.66
-96.40
-50.83
Shares, basic (weighted)
0.01
0.08
0.31
0.31
0.52
0.55
0.77
Shares, diluted (weighted)
0.01
0.08
0.31
0.31
0.52
0.55
0.77
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
3.92
157
42.7
24.5
96.3
38.8
48.9
Short-term investments
46.2
54.6
0
Receivables
0
Other current assets
0.51
0.28
0.4
1.21
1.97
2.28
2.85
Total current assets
4.65
160
91.9
83.6
102
44.2
52.1
Property, plant and equipment
0.07
0.14
Lease right-of-use assets
1.79
1.48
1.4
Long-term investments
32.5
0
Other non-current assets
0.04
0.48
0.65
0.64
0.58
0.07
0.24
Total assets
4.69
163
126
85.6
104
45.2
53
Accounts payable
1.88
3.63
2.82
1.43
3.33
1.3
0.94
Accrued liabilities
14.6
12.3
9.14
Deferred revenue
0
4.91
0
Short-term debt
1.25
2.55
0
1.62
1.62
1.62
0
Total current liabilities
4.3
9.76
8.87
12.4
24.5
15.2
10.1
Long-term debt
3.19
1.92
4.88
3.29
1.72
0.12
0
Lease liabilities
1.65
1.29
1.26
1.02
0.74
0.42
Other non-current liabilities
0.02
0.12
0.07
0.16
0.24
0.28
0
Total liabilities
7.52
13.5
15.1
17.2
27.4
16.4
10.5
Total debt
4.45
4.48
4.88
5.64
3.71
1.84
0
Paid-in capital
0.66
210
215
218
274
279
332
Retained earnings
-31.3
-60.8
-103
-149
-197
-250
-289
Other comprehensive income
-0.18
-0.56
0
Shareholders' equity
-30.6
149
111
68.5
76.5
28.8
42.5
Total equity
-30.6
149
111
68.5
76.5
28.8
42.5
Total liabilities and equity
4.69
163
126
85.6
104
45.2
53
Shares outstanding
0.01
0.31
0.31
0.32
0.55
0.56
1.37
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-13.1
-29.5
-42.3
-46.2
-47.9
-53
-39
Depreciation and amortization
0.01
0.04
0.07
0.07
0.07
0.05
0.02
Stock-based compensation
0.2
0.76
3.96
3.63
4.62
5.35
2.57
Change in payables
-0.23
3.73
-0.81
-1.4
1.91
-2.04
-0.35
Cash from operations
-12.6
-27.5
-35.9
-41.7
-33.3
-56
-33.3
Capital expenditures
-0
-0.07
-0.09
-0.01
-0.01
0
Purchases of investments
-79.1
-36.8
-11.9
0
Sales and maturities of investments
0
60.5
67.7
0
Cash from investing
-0
-0.07
-79.2
23.7
55.8
0
Debt issued
4.49
4.99
0
Debt repaid
-4.77
0
-1.62
-1.62
-2.06
Stock issued
0.05
0.33
0
0
0.18
0.01
Cash from financing
12.4
181
0.64
-0.24
49.1
-1.62
43.5
Net change in cash
-0.19
153
-114
-18.2
71.6
-57.6
10.2
Free cash flow
-12.6
-27.6
-36
-41.7
-33.3
-56
Interest paid
0.02
0.19
0.21
0.27
0.37
0.23
0.07
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $48.72 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-61.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-49.9%
Net income / average total assets.
Return on invested capital (ROIC)
-512.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-100.0%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
47.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-14.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-22.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
17.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-14.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-20.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
39.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
34.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
57.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
9.23x
Current assets / current liabilities.
Quick ratio
8.78x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
8.78x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.24x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
19.4%
Total debt / total assets.
Liabilities / assets
18.6%
Total liabilities / total assets.
Net debt
-$76.4M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$17.53
Cash from operations / diluted weighted shares.
Book value per share
$30.42
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.67x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.67x
Market cap / tangible book value, when positive.
Earnings yield
-36.7%
Net income / market cap (the inverse of P/E).
What was SPRUCE BIOSCIENCES, INC.'s revenue in fiscal 2025?
SPRUCE BIOSCIENCES, INC. reported revenue of $0.0 for fiscal 2025, 100% lower than the year before.
Was SPRUCE BIOSCIENCES, INC. profitable in fiscal 2025?
No. It reported a net loss of $39.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.